— Know what they know.
Not Investment Advice
Also trades as: ESLAW (NASDAQ) · $vol 0M

ESLA NASDAQ

Estrella Immunopharma, Inc.
1W: -2.7% 1M: -32.2% 3M: -54.1% YTD: -66.3% 1Y: -65.1% 3Y: -95.7% 5Y: -95.2%
$0.47
-0.01 (-1.47%)
 
Weekly Expected Move ±12.3%
$0 $0 $0 $1 $1
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 27 · $20.0M mcap · 17M float · 0.239% daily turnover · Short 34% of daily vol

Balance Sheet Trends

Total Assets
$3M +1.2% ▲
4Y CAGR: -10.4%
Total Liabilities
$14M +351.9% ▲
4Y CAGR: +22.8%
Shareholders Equity
-$10M -7312.1% ▼
Cash & Investments
$1M +51.0% ▲
4Y CAGR: -23.7%
Total Debt
$0 +0.0% ▲
Net Debt
-$1M -51.0% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$4M$41K$4M$917K$1M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$4M$41K$4M$917K$1M
Net Receivables$0$0$289K$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$0$0$724K$293K
Total Current Assets$5M$52K$4M$2M$2M
Property, Plant & Equip.$0$0$0$0$0
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$45M$10M$0$0$0
Other Non-Current Assets$0$0$0$2M$2M
Total Non-Current Assets$45M$10M$0$2M$2M
Total Assets$5M$10M$4M$3M$3M
— Liabilities —
Accounts Payable$946K$47K$0$0$555K
Short-Term Debt$0$499K$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$0$9M$130K$3M$13M
Total Current Liabilities$947K$1M$181K$3M$14M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$5M$2M$0$0$0
Total Non-Current Liabilities$5M$2M$0$0$0
Total Liabilities$6M$3M$181K$3M$14M
— Equity —
Common Stock$18$9M$4K$4K$4K
Retained Earnings-$1M-$2M-$20M-$24M-$37M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity-$1M$7M$4M$144K-$10M
Total Liabilities & Equity$5M$10M$4M$3M$3M
— Key Metrics —
Total Debt$0$499K$0$0$0
Net Debt-$4M$458K-$4M-$917K-$1M
Total Investments$45M$10M$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms